A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-04-03 DOI:10.1080/17512433.2024.2337012

Simona Lattanzi, Eugen Trinka, Stefano Meletti, Pasquale Striano, Sara Matricardi, Mauro Silvestrini, Francesco Brigo

引用次数: 0

Abstract

Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of indiv...

查看原文本刊更多论文

用于治疗癫痫的氮杂环丁烷概况：从药理学到治疗潜力

癫痫是一类多发性脑部疾病，抗癫痫药物（ASM）是治疗癫痫的主要药物。尽管目前有 30 多种药物可供选择，但至少有三分之一的人仍在服用这些药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.